Avacta Share Discussion Threads

[hampton58] 08/1/2019 14:46

Remember it was over 100 p a year ago

[hampton58] 08/1/2019 14:46

Directions new options scheme should inspire them

[babbler] 08/1/2019 14:40

60p plus year end.

[pugugly] 08/1/2019 14:13

Dan - Agreed te t/o possibility - Big pharmas paying some rediculous prices-
Bum - Hence asking if tipped - A pofit is a pofit - A few big volume sells appear to be going through (100K plus) not the smaller PI sells. 43% in less than 5 months nice for some.

[danatkins] 08/1/2019 14:10

If January turns out to be negative on global markets then watch out for the bear. If we can keep the gains for Jan then new all time high coming in US markets. Let's see how the January affect plays out

[cf456] 08/1/2019 14:09

Instis have been happy to load up significantly in recent weeks, fully aware of the significant upside potential here.

Lombard Odier - up to 6.43% from 4.63%.
JO Hambro - up to 10.91% from 5.03%
Mole Valley - up to 3.01%

With multiple further licencing agreements expected in coming months, they know that it will be difficult to buy in such a size at a later date.

If the price can shoot up so strongly on the open as it did on the 10th December last year with the LG Chem deal, then it can do this several times again with each new agreement.

[hampton58] 08/1/2019 14:09

Gentlemen,The company have not only recently delivered the LG Deal and significant change of the shareholder register.At the same time , we have the largest gathering of buy side and companies in SAN Francisco at the JP Healthcare conference and the Bio tech Showcase.Accelerating M&A in the sector and we are very likely to see further deals being announced by the company.Going forward we will have days like this , but the important thing is that there are buyers of this stock and that will remain the fact for some time .

[nobbygnome] 08/1/2019 14:07

>>pug

WRT TLY, just wait for the announcement of the IUC contract wins.....

Sorry for being off topic everyone!

[danatkins] 08/1/2019 14:06

50p here very soon!

[danatkins] 08/1/2019 14:04

Bear market is still debatable. Markets still in a bull market on monthly charts. Still the opportunity here is stagering. Buy the dips/oversold conditions. Waiting for my SIPP transfer and the price is running away lol. Anyone with half a brain will realise the potential hear with a possible take over in the future regardless of bear market.

[bumpa33] 08/1/2019 13:55

stunning analysis of the situation Pug..! :)

[pugugly] 08/1/2019 13:43

Anyone know if this is a New Year tip anywhere?
Volume has been on an upward trend for the last few days - Reason I ask is if a bucket shop tip, then high probability of stop-losses kicking in, in the medium term future. Unless further encouraging product development news- Also there well may be some of those who participated in the rights issue motivated to lock in a 10p+ profit in what looks a though may be a developing BEAR market.

[cf456] 08/1/2019 13:36

Good volume today accompanying the rise.

There are plenty of buyers taking positions by the looks of it.

[pugugly] 08/1/2019 13:35

Hi Nobby - You still in TLY? If so could be well on the way to covering your losses there with AVCT. Subject of course to timing!! - Have a prosperous New Year -

[nobbygnome] 08/1/2019 13:30

So following the price action today, I withdraw my earlier comment 😜. I have bought a few more via spreadbet this morning. The price certainly looks very strong from a TA point of view....

[tomboyb] 08/1/2019 12:05

Pricing looks good -

A bit more patience and we could be late 30s -

Good luck -

[hampton58] 08/1/2019 12:04

They will there at Avacta Science Day

[hampton58] 08/1/2019 12:03

34-35 at midday, we were right

[bumpa33] 08/1/2019 11:52

10.20

As for the Tufts/Avacta collaboration - using affimers in targeting and "lighting up" cancer cells, so that the body's immune system can first see, and then destroy, tumors - well, the potential implications are obvious...

[bumpa33] 08/1/2019 11:39

also very pertinent point re: Asian pharma being very interested in non-antibody solutions/applications where they are not constrained/blocked by IP in the current antibody field.

[hampton58] 08/1/2019 11:35

Cash is king and that is something the major Pharma's got plenty of.Watch more RNS ref shareholder register

[hampton58] 08/1/2019 11:33

The majors all wants to be in the Immuno-oncology area and are therefore paying attention to the potential of the Affimer business

[bumpa33] 08/1/2019 11:29

very impressive presentation actually, i've just listened through it again. Critical for me here is the work of Affimers as a targeted drug delivery platform, across a whole field of therapeutics, rather than merely a specific/single drug. The potential is truly enormous, especially with just a couple of competitors - Ablynx having been taken over. And then there is the backup of the diagnostics business. The wider market surely has to wake up to this sooner or later.